PCI Biotech Holding Past Earnings Performance

Past criteria checks 0/6

PCI Biotech Holding's earnings have been declining at an average annual rate of -16.8%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 13.6% per year.

Key information

-16.8%

Earnings growth rate

-7.8%

EPS growth rate

Biotechs Industry Growth	11.5%
Revenue growth rate	-13.6%
Return on equity	-115.7%
Net Margin	-1,545.9%
Next Earnings Update	17 Feb 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How PCI Biotech Holding makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BATS-CHIXE:PCIBO Revenue, expenses and earnings (NOK Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 22	5	-73	17	61
30 Jun 22	5	-84	16	73
31 Mar 22	6	-88	17	77
31 Dec 21	6	-88	21	72
30 Sep 21	7	-90	19	72
30 Jun 21	7	-90	18	74
31 Mar 21	7	-100	18	77
31 Dec 20	7	-72	14	76
30 Sep 20	8	-71	18	76
30 Jun 20	8	-64	16	74
31 Mar 20	9	-61	14	82
31 Dec 19	9	-89	15	83
30 Sep 19	10	-68	15	73
30 Jun 19	10	-62	14	64
31 Mar 19	10	-43	14	44
31 Dec 18	10	-35	14	40
30 Sep 18	10	-46	13	43
30 Jun 18	10	-48	14	44
31 Mar 18	10	-48	13	45
31 Dec 17	10	-43	13	41
30 Sep 17	10	-34	10	35
30 Jun 17	10	-33	8	36
31 Mar 17	10	-35	6	40
31 Dec 16	10	-32	4	39
30 Sep 16	11	-34	4	41
30 Jun 16	11	-34	4	41
31 Mar 16	10	-31	4	38
31 Dec 15	10	-32	4	39

Quality Earnings: PCIBO is currently unprofitable.

Growing Profit Margin: PCIBO is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: PCIBO is unprofitable, and losses have increased over the past 5 years at a rate of 16.8% per year.

Accelerating Growth: Unable to compare PCIBO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PCIBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).

Return on Equity

High ROE: PCIBO has a negative Return on Equity (-115.69%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/12/06 13:32
End of Day Share Price	2022/09/08 00:00
Earnings	2022/09/30
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PCI Biotech Holding ASA is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Hans Bohn	Beringer Finance AB